
Partner @AverinCapital | Biotech, Healthcare, AI | Scout Partner @Sequoia | ex-@a16z | MD Yale, MBA Harvard
San Francisco, CA
Joined July 2011
- Tweets1.3K
- Following1.7K
- Followers3.4K
- Likes3.8K
Pinned Tweet
Everyone said AI would eat biology.
A decade later, AI is the one getting indigestion.
Here’s what actually happened - and what the new wave of GenAI biotechs need to learn:
🧵 1/
You know you’ve made it when you get your first impersonation scam 😅
Someone is pretending to be me on Telegram and contacting people, particularly in crypto. The Telegram account @jeffreylowmd is NOT me.
Please don’t engage and report the account if it contacts you.
5
7
366
This year I’ve gotten half a dozen different cold company pitches ending with “Is this something you’re not interested in? Just say so and I’ll take my hive elsewhere”
What service is this?
1
3
396
I logged 68,660 foods over 15 years.
The months I lost fat were not the months I ate the least. They were the months I cut moderately and stayed active.
When I cut harder, it backfired. Aggressive deficits raised my resting heart rate on a 4-6 week delay. And when RHR was elevated, the same deficit did nothing (r = 0.54 vs 0.07).
Hard dieting triggers the stress response that prevents hard dieting from working.
The harder I cut, the less weight I lost.
5
406
Built a health dashboard at 3am during paternity leave with Claude Code. No engineering background.
Pulls my labs, trends everything, generates a printout I hand my doctor.
Every health app gives you 50+ metrics and no context. The value isn’t the dashboard. It’s knowing what belongs on it.
What would you put on yours?
The biotech industry crowds into consensus right before the biggest returns are created elsewhere.
The strongest biotech vintage of the last 20 years was built when capital was most afraid.
👇 nitter.cf/JeffreyLowMD/status/20…
1
3
395
I wrote a longer piece expanding on this pattern, the companies behind it, and why I think we’re at a similar moment today:
averincapital.com/insights/w…
Biotech can solve the impossible.
It just can’t explain itself.
The real story behind drug costs:
• The Iceberg Effect
People see price tags, not the decade of risk and failure beneath them.
• The Lifecycle of Value
Drugs are expensive when new and cheap for society once they become generics.
• The Insurance Gap
Most access problems come from insurance design, not innovation.
If we told this story clearly, the debate around access would look very different.
Biotech doesn’t just need more innovation.
It needs more translators.
If the industry gets this right, everything else gets easier.
Too many platform companies were judged on the wrong asset.
Not because the science was bad.
Because the first program was picked for speed instead of strategy.
Early “lead programs” are rarely the best expression of a platform. They get chosen for comfort-zone biology, easy readouts, or fast fundraising.
The cost is huge.
Markets anchor on rushed programs, not the platform’s real advantage.
Your first program isn’t a demo. It’s a declaration. Pick it like it decides your fate. It probably will.
2
392
The exit cycle in biotech and health care is changing fast.
If you care about IPO timing, M&A appetite, or the real exit landscape for 2026, join @averincapital for this one hour webinar.
The New Liquidity Landscape
Thu Dec 11, 11am to 12pm EST
Moderated by @DavidBerry26, Averin
With:
John Bishai, JP Morgan
Paul Kinsella, Ropes & Gray
Will Herrmann, Citi ECM
Topics:
• What the 2026 IPO window really looks like
• What strategics are prioritizing now
• How to think about SPACs and Direct Listings
Link in the first comment.
266
For @averincapital, this is a major milestone.
It will be our first portfolio company with a clear route to the public stage and reflects the type of science driven platform we aspire to back.
2
1
240
The road from a seed deck to a public company is brutal.
I want to acknowledge the original crew around that poker table who built the 0 to 1 foundation:
@GabeOtte
Riley Ennis
@CCRobertsARK
1
1
239
You created the vision that made everything else possible.
To the entire Freenome team, past and present: congratulations.
freenome.com/newsroom/freeno…
184





